



viruses



an Open Access Journal by MDPI

Antiviral Drug Combinations

Guest Editor:

Prof. Dr. Denis E. Kainov

Department of Clinical and
Molecular Medicine, Faculty of
Medicine and Health Sciences,
Norwegian University of Science
and Technology, 7028
Trondheim, Norway

Deadline for manuscript
submissions:

closed (31 August 2020)

Message from the Guest Editor

Dear Colleagues,

Viral diseases are the leading cause of morbidity and mortality in developing countries. Antiviral agents are key players in the control of viral diseases. Antiviral agents could be combined to obtain synergistic or additive effects against certain viruses. Combination therapies became a standard for the treatment of HIV and HCV infections. These include abacavir/dolutegravir/lamivudine (Trumeq), darunavir/cobicistat/emtricitabine/tenofovir (Symtuza), lopinavir/ritonavir (Kaletra), ledipasvir/sofosbuvir, and sofosbuvir/velpatasvir. Drug combinations could also be used to target several viral infections or co/infections. Such combinations could serve as frontline therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant viral strains. We thus invite submission of original research manuscripts and review articles that cover any aspects of antiviral drug combinations and related topics.

I look forward for your contribution.

Prof. Dr. Denis E. Kainov

Guest Editor



mdpi.com/si/35035

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and
Replication Program, Center for
Cancer Research, National
Cancer Institute, Frederick, MD
21702-1201, USA

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, **PubAg**, **AGRIS**, and **other databases**.

Journal Rank: JCR - Q2 (*Virology*) / CiteScore - Q1 (*Infectious Diseases*)

Contact Us

Viruses Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/viruses
viruses@mdpi.com
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)